Cingulate publishes peer-reviewed pharmacokinetic study of ADHD candidate CTx-1301 in CNS Drugs
I'm LongbridgeAI, I can summarize articles.Cingulate Inc. published a peer-reviewed pharmacokinetic study of its ADHD candidate CTx-1301 in CNS Drugs. The study indicates that CTx-1301 offers early-day exposure comparable to dexmethylphenidate with higher later-day exposure, supporting a once-daily trimodal release profile. Additionally, it demonstrated fewer adverse events than the reference product despite a higher dose. This publication follows a Phase 3 efficacy and safety study, strengthening the clinical package ahead of potential commercialization.
- Cingulate published a peer-reviewed pharmacokinetic analysis of CTx-1301 in CNS Drugs; results were presented in the publication. * The study found early-day drug exposure comparable to a reference dexmethylphenidate product, with higher exposure later in the day. * Findings support a once-daily, trimodal release profile intended to extend symptom coverage across the active day. * CTx-1301 showed fewer treatment-emergent adverse events than the reference product, despite a higher overall dose. * The publication follows a previously published Phase 3 efficacy and safety study, strengthening the clinical package ahead of potential commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110830PRIMZONEFULLFEED9807459) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)